Pharmaceutical and Medicinal Product Manufacturing

ANZSIC group 184 · 22 mergers

Since February 2026, the ACCC has reviewed 22 acquisitions in the Pharmaceutical and Medicinal Product Manufacturing industry (ANZSIC group 184): 14 notified mergers and 8 waiver applications. Of these, 1 was referred to Phase 2. Outcomes so far: 18 approved, 2 not approved and 2 still under assessment. The most frequent acquirers are Eli Lilly (6) and Gilead (2). Completed Phase 1 reviews took a median of 17 business days, and waivers a median of 18 business days. The most recent, Sun Pharma - Organon, was lodged on 22 October 2026.

Total reviews

22

Phase 2 reviews

1

Waivers

8

Under assessment

2